Article Details
Retrieved on: 2021-03-30 12:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here